Method Peptides · Research compound

CJC-1295 (No DAC)

$45.00
DOSE
≥99% purity
Third-party tested
Ships from the USA
Secure, discreet packaging
ShippingFree on orders $200+

$15 flat rate on orders under $200.

FulfillmentEstimated 2–5 business days

Tracking is provided when the order ships.

Review return policy →

Research reference

Compound overview

Product specifications, research context, and handling information.

CJC-1295 (No DAC)

CJC-1295 (No DAC), commonly referred to as Modified GRF (1–29), is a synthetic GHRH analog supplied without a Drug Affinity Complex.

Research examines GHRH receptor activation, pituitary responses, and shorter-duration endocrine signaling relative to DAC-modified analogs.

Key Research Areas

  • GHRH receptor signaling
  • Pituitary-response models
  • GH pulse-related research
  • DAC versus non-DAC comparisons

Mechanism of Interest

The modified GHRH sequence interacts with GHRH receptors. Without the DAC group, it lacks the albumin-conjugating modification used to prolong exposure in CJC-1295 DAC.

Product Details

Format: Lyophilized material in vial format
Available Options: 5 mg per vial; 10 mg per vial
Compound Class: Modified GHRH (1–29) analog without DAC
Compound: CJC-1295 (No DAC)
Storage: Follow the product label and lot-specific storage instructions. Prepared-sample storage depends on formulation and validated laboratory stability conditions.

Timing Matters in GHRH Research

The non-DAC form is relevant to studies of shorter-duration GHRH activity and growth hormone release patterns. Comparisons with DAC-modified analogs examine how exposure duration shapes the endocrine response.

Research Use Only:

This product is intended strictly for laboratory and research purposes. Not for human consumption, medical use, diagnostic use, or therapeutic use.